Real World Evidence of Clinical Outcomes of First-Line Chemotherapy in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Patients

Document Type : Research Articles

Authors

1 Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

2 Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Abstract

Purpose: Pancreatic cancer has poor prognosis, with a five-year survival rate of approximately 10%. This study evaluated the clinical outcomes of first-line chemotherapy (CMT) for patients with locally advanced and metastatic pancreatic ductal adenocarcinoma (LA/M-PDAC). Patients and Methods: A retrospective chart review was conducted of patients with LA/M-PDAC who underwent CMT between January 2008 and December 2018. Efficacy data (objective response rate [ORR], disease control rate [DCR], progression-free survival [PFS], and overall survival [OS]) were evaluated and compared using Pearson’s chi-squared tests, Kaplan–Meier plots, and log-rank tests. Results: Of 998 patients diagnosed with LA/M-PDAC, 332 (33.3%) underwent systemic CMT. Among the treatment regimens used, gemcitabine (GEM) was most commonly administered (33.7%). The next most common therapies were (m)FOLFIRINOX and GEM plus capecitabine (GEMCAPE), accounting for 27.4% and 26.2% of cases, respectively. The ORRs were 4.5, 10.3, 23.1, and 19.4% for GEM, GEMCAPE, (m)FOLFIRINOX, and Platinum doublets (PlatD), respectively. Patients who received combination CMTs had significantly longer median PFS than those who received GEM alone (PFS = 4.93 months (mos) for GEMCAPE, 9 mos for (m)FOLFIRINOX, 9.43 mos for PlatD, and 3.87 mos for GEM). However, no significant differences were observed in the median OS rates among the four regimens. The treatment-related grade 3 or 4 adverse events were highest in the (m)FOLFIRINOX group. Conclusion: In the first-line treatment of PDAC, (m)FOLFIRINOX exhibited higher ORR and PFS than GEM or GEMCAPE. However, no survival advantage was observed in the (m)FOLFIRINOX group, suggesting an influence of subsequent therapy.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 27, Issue 1
January 2026
Pages 371-380

Files

History

  • Receive Date: 10 July 2025
  • Revise Date: 26 August 2025
  • Accept Date: 05 January 2026

Share

How to cite

Statistics